Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin

Share this content:
Cachexia is a common side effect of advanced cancer
Cachexia is a common side effect of advanced cancer

Anamorelin effectively relieves anorexia-cachexia in patients with advanced non-small cell lung cancer (NSCLC), according to a study published in Palliative Care: Research and Treatment.

Cachexia is a commonly reported syndrome in patients with advanced cancer and presents as weight loss, anorexia, muscle breakdown, and is associated with poor prognoses in patients. Previous studies have demonstrated that anamorelin, an analogue of the satiety hormone ghrelin, may improve cachexia symptoms.

In this study, data from three phase 2 studies and two phase 3 studies are presented.

In a phase 2, blinded, crossover study, 16 patients were randomly assigned to anamorelin 50 mg once daily or placebo for 3 days. After a 3 to 7 day washout period, the patients switched arms. Body weight increased by 0.77 kg in patients receiving anamorelin, whereas a 0.33-kg loss was seen in patients receiving placebo (P =.016).

In a second phase 2 study, this one a 3-day crossover design study, 82 patients with various solid tumors randomly received anamorelin or placebo. Patients in the anamorelin group and placebo group experienced a weight change of 1.89±0.53 kg and –0.20±0.52 kg, respectively (P =.0006).

In the final presented phase 2 study, researchers enrolled 226 patients to receive anamorelin 50 mg, anamorelin 100 mg, or placebo. Patients who received anamorelin 100 mg gained 0.14 kg, while weight changes in patients receiving anamorelin 50 mg or placebo were –0.3 kg and –1.32 kg, respectively. The average difference seen in patients receiving anamorelin 100 mg vs 50 mg was 1.47 kg (P  =.0005).  

Page 1 of 2
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs